Multiple myeloma carries the highest relative heart attack risk among 13 cancer subtypes, according to a nationwide Danish study published on Sunday.
Researchers analyzed registry data from 660,531 adults diagnosed with cancer between 2000 and 2023. Patients with a prior heart attack or coronary revascularization before their cancer diagnosis were excluded from the analysis.
The study compared outcomes across cancer subtypes using patients with low-risk skin tumors as the reference group. Multiple myeloma showed a relative myocardial infarction risk of 1.80 times that of the reference group, with a 95% confidence interval ranging from 1.34 to 2.26.
Elevated relative risks also appeared in several other cancer categories. Bladder cancer showed a relative risk of 1.52, kidney cancer reached 1.51, leukemia registered at 1.45, and gastrointestinal cancer recorded 1.37.
| Cancer Subtype | Relative Risk | Standardized Absolute Risk |
|---|---|---|
| Multiple Myeloma | 1.80 | 0.91% |
| Bladder Cancer | 1.52 | 0.86% |
| Kidney Cancer | 1.51 | 0.72% |
| Leukemia | 1.45 | Not reported |
| Gastrointestinal Cancer | 1.37 | Not reported |
| Breast Cancer | Reference / Other | 0.31% |
Despite these differences in relative risk, the standardized one-year absolute heart attack risk remained below 1% across all evaluated cancer subtypes. Estimates spanned from 0.31% in breast cancer up to 0.91% in multiple myeloma, with bladder cancer at 0.86% and kidney cancer at 0.72%.
One-year all-cause mortality varied substantially across the cancer groups, ranging from 2.2% in patients with low-risk skin tumors to 71.9% in those with hepatobiliary and pancreatic cancer. The study authors emphasized that this competing risk of death is important when interpreting early cardiovascular outcomes, noting that a lower observed incidence of heart attacks does not necessarily indicate lower underlying cardiovascular susceptibility when cancer mortality is high.
The observational study, authored by Jan Walter Dhillon Shanmuganathan, Joachim Baech, Christoffer Bech Polcwiartek et al. and published in the International Journal of Cardiology, lacked consistent detailed information on cancer treatment regimens, timing, and certain lifestyle-related cardiovascular risk factors. Whether these associations hold across other populations and treatment eras remains unclear.